Published in J Immunother Emphasis Tumor Immunol on August 01, 1993
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med (1996) 1.83
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med (2008) 1.31
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24
A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res (2012) 1.14
Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc Natl Acad Sci U S A (2004) 1.11
Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. Mol Cell Proteomics (2015) 1.05
ER stress affects processing of MHC class I-associated peptides. BMC Immunol (2009) 1.02
Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci U S A (1999) 0.98
T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol (2004) 0.94
Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J Exp Med (1997) 0.93
Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease. J Clin Invest (1996) 0.88
Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer (2001) 0.84
LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens. Immunology (2010) 0.83
Contrasting effects of anti-Ly49A due to MHC class I cis binding on NK cell-mediated allogeneic bone marrow cell resistance. J Immunol (2013) 0.82
The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol (2017) 0.82
Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu. Mol Immunol (2006) 0.79
Adapter-mediated substrate selection for endoplasmic reticulum-associated degradation. J Biol Chem (2009) 0.79
Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigen-encoding genetic information. Proc Natl Acad Sci U S A (2012) 0.77
Generation of an effective anti-lung cancer vaccine by DTPP-mediated photodynamic therapy and mechanistic studies. Lasers Med Sci (2013) 0.76
The nature of peptides presented by an HLA class I low expression allele. Haematologica (2010) 0.75
Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors. Environ Health Perspect (2006) 0.75
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ (2011) 5.95
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics (1985) 5.30
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J (1986) 3.78
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol (1987) 3.06
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia (2010) 2.83
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc Natl Acad Sci U S A (1990) 2.37
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature (1988) 2.25
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol (1986) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. Proc Natl Acad Sci U S A (1991) 2.07
Nature of polymorphism in HLA-A, -B, and -C molecules. Proc Natl Acad Sci U S A (1988) 2.05
Increase in the 64-kDa subunit of the polyadenylation/cleavage stimulatory factor during the G0 to S phase transition. Proc Natl Acad Sci U S A (1998) 2.01
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med (1988) 1.98
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol (1980) 1.81
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol (1989) 1.75
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol (1993) 1.69
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 1.60
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol (1990) 1.59
Early versus delayed shoulder motion following axillary dissection: a randomized prospective study. Ann Surg (1981) 1.54
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res (2001) 1.51
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol (1985) 1.50
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol (1994) 1.49
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol (1989) 1.46
In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J Immunol (1980) 1.44
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med (1987) 1.44
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med (1995) 1.42
In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J Immunol (1989) 1.41
Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci U S A (1990) 1.36
In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. J Immunol (1981) 1.36
Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med (1996) 1.36
Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg (1998) 1.32
Mass spectrometric identification of increased C16 ceramide levels during apoptosis. J Biol Chem (1999) 1.32
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med (1996) 1.32
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther (1996) 1.31
Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol (1988) 1.30
Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol (1996) 1.29
Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol (1981) 1.29
IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol (1998) 1.28
Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes (1999) 1.27
Regulatable systems: applications in gene therapy and replicating viruses. J Clin Invest (2000) 1.27
Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol (1999) 1.26
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol (1995) 1.26
Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol (1995) 1.25
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med (1995) 1.24
Calnexin recognizes carbohydrate and protein determinants of class I major histocompatibility complex molecules. J Biol Chem (1995) 1.23
Calnexin influences folding of human class I histocompatibility proteins but not their assembly with beta 2-microglobulin. J Biol Chem (1995) 1.23
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol (1999) 1.22
The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol (1984) 1.22
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med (1988) 1.22
Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood (2001) 1.21
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res (1996) 1.17
Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol (1996) 1.17
Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res (2000) 1.16
Evidence for two trans-acting genes regulating HLA class II antigen expression. J Immunol (1985) 1.16
CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res (2000) 1.15
In vitro mutagenesis at a single residue introduces B and T cell epitopes into a class I HLA molecule. J Exp Med (1987) 1.14
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther (2007) 1.14
Interleukin 2 and psoriasis. Arch Dermatol (1988) 1.14
IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J Immunol (1989) 1.12
FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol (1997) 1.12
Peptide-induced modulation of target cell sensitivity to natural killing. J Immunol (1992) 1.12
Apoptosis promotes early tumorigenesis. Oncogene (2010) 1.11
Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol (1988) 1.11
HLA-DR characterization of a Chippewa Indian subpopulation with high prevalence of rheumatoid arthritis. Hum Immunol (1981) 1.11
Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark (2005) 1.10
Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol (1994) 1.10
Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther (2001) 1.09
Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol (1994) 1.08
Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther (1999) 1.08